Trial Profile
An Extended Access Program (EAP) for Perampanel
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Expanded access; Therapeutic Use
- Sponsors Eisai Inc
- 04 Dec 2018 Results of post hoc analysis assessing primary generalized tonic-clonic (PGTC) seizures, presented at the 72nd Annual Meeting of the American Epilepsy Society.
- 27 Apr 2018 Results of post-hoc analysis from this open-label extension phase assessing the effect of common concomitant antiepileptic drugs during adjunctive treatment with Perampanel, presented at the 70th Annual Meeting of the American Academy of Neurology.
- 27 Apr 2018 Results of a post-hoc analysis from NCT00735397, NCT01618695, NCT01161524 and NCT02307578 studies, presented at the 70th Annual Meeting of the American Academy of Neurology